Tan M, et al. - Researchers examined whether dual therapy with lamivudine (3TC), with dose adjustment for renal function, and dolutegravir (DTG) is effective in a subgroup of patients fully suppressed on treatment who were switched because of concerns about comorbidity and toxicity on their current triple drug regimen. As per data extracted from an electronic patient record of a single-center, among 52 patients (median age of 60.5 years), no virological failures occurred during the median follow-on dual therapy of 2.29 years (28 months; range 1.10–3.34 years). Considering the reduced renal function, the dose of 3TC was adjusted in 25 of 52 (48%) cases, and none of these patients experienced virological failure. Findings suggest the possible efficacy of 3TC and DTG in controlling viral load in older patients with comorbidities. In the context of comorbidities (including renal impairment) and polypharmacy in older patients, this regimen seems a useful option.